Trade deal will 'force' FDA, EMA to standardize regs; Lundbeck touts Abilify data; Mylan CFO aims for TASE;

@FiercePharma: India's Kumar eyes a one-stop shop on pharmaceuticals. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: See which companies had the most Class I recalls in recent years. Feature from FiercePharmaManufacturing | Follow @EricPFierce

> A transatlantic trade deal will force the FDA and European Medicines Agency to standardize their regulations on manufacturing and trials, an Eli Lilly ($LLY) executive recently said. Report

> Lundbeck said a new data analysis showed its long-lasting antipsychotic injection Abilify Maintena beat head-to-head rival Invega Sustenna at improving functioning and quality of life in young people with schizophrenia. Release

> Mylan ($MYL) CFO John Sheehan said the company wants to join the Tel Aviv Stock Exchange (TASE) if it succeeds in buying Perrigo ($PRGO); it would be among the largest publicly traded companies on Israel's exchange. Report

> Pozen, which just swapped CEOs and engineered a tax-inversion buyout, brought in three new top managers to lead the combined company, which will be called Aralez Pharmaceuticals. Report

> Morris Plains, NJ, cracked down on environmental remediation plans for a former Pfizer ($PFE) site in the borough. Report

> NeuroRx said a small study of a ketamine drug combination reduced symptoms of depression and suicidal tendencies in patients with bipolar disorder. Report

Medical Device News

@FierceMedDev: Broad Institute bags $20M for drug-resistant TB research. More from FierceDiagnostics | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Medtronic strikes back with FDA approval of its third-gen TAVR. Report | Follow @VarunSaxena2

@EmilyWFierce: Cue the screaming fans: Nick Jonas signs up with Dexcom diabetes effort. FiercePharmaMarketing story | Follow @EmilyWFierce

> The Esophageal Cooling Device gets FDA's rare de novo clearance for innovative devices. Article

> Philips readies launch of smart device-based ultrasound device, app. Story

Biotech News

@FierceBiotech: Chris Viehbacher explains: "If I had $2 billion to invest ..." More | Follow @FierceBiotech

@JohnCFierce: Cool new video on Cellectis's allogeneic approach to T cells. It looks so easy... Watch | Follow @JohnCFierce

@DamianFierce: Analyst on $ADHD call: "congrats on these interesting observations." Their drug was outperformed by placebo, dude. | Follow @DamianFierce

> Langer startup SQZ hopes to spark a tech revolution in immuno-oncology. Article

> Hackers are targeting biotech with eyes on insider trading. Report

Biotech Research News

> Team spotlights new evidence that Parkinson's starts in the gut. Story

> Allied-Bristol JV picks up rights to Harvard's work on traditional Chinese remedy. News

> Experimental prostate cancer combo shows promise in case studies. Report

> Purdue group finds Achilles' heel for MERS. Item

> Investigators say they've designed a new-and-improved antibiotic. Article

Diagnostics News

> Qiagen to partner with Japan's Hitachi on molecular testing. More

> Broad Institute bags $20M for drug-resistant TB research. Item

> Advanced Cell Diagnostics receives $22M to develop its RNA biomarker tech. News

> Siemens snags FDA approval for HIV combo test. Story

> Biodesix brings Series E to $38M for blood-based lung cancer Dx. Article

Pharma Marketing News

> Another AZ exec jumps ship for CEO job at smaller drugmaker. Item

> Novartis playing catch-up in cancer? Not us, says top oncology exec. Story

> Has Lundbeck failed to sharpen Brintellix's marketing edge with payers? More

> Call it Allergan, call it a 'growth pharma.' Just don't call it Big Pharma. Article

> Got game? Pharma's moving into gamification but needs to drop the bribes. Report

And Finally... An 18-year-old Thiel Fellow postponed college for a year to develop and sell GlucoIQ, his platform for doctors to use in managing diabetes patients' medications and outcomes. Report

Suggested Articles

The lawsuit is part of a years-long battle between the Cochrane Collaboration and Roche around Tamiflu's use against pandemic influenza.

Takeda forged a feasibility pact to see whether it could pair a plasma-based therapy with Elektrofi's microparticle delivery tech.

Sanofi's Dupixent is set to reach $12.5 billion in peak sales, Jefferies analysts wrote, affirming CEO Paul Hudson's focus on the immunology med.